Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Fresenius Propoven 2% Emulsion | NLM

Disaster Information Management Research Center | NLM

Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Fresenius Propoven 2% Emulsion

05/08/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/8/2020. This nine-page details the Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Fresenius Propoven 2% (propofol 20 mg/mL) Emulsion 100 mL, to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an intensive care unit (ICU) setting during the 2019 coronavirus disease (COVID-19) pandemic. (PDF)